07:27 AM EST, 01/17/2025 (MT Newswires) -- Novartis ( NVS ) has obtained a temporary order from the US Court of Appeals for the Federal Circuit, preventing MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto, according to the court order on Thursday.

MSN Pharmaceuticals had planned to launch its generic on Thursday, coinciding with the expiration of Novartis' ( NVS ) patent, Reuters reported late Thursday.

The court said it decision would allow time to consider Novartis' ( NVS ) request for a longer ban on the generic release.

The decision comes after the Federal Circuit last week overturned a 2023 ruling that invalidated one of Novartis' ( NVS ) patents, which the company argued protects its exclusive rights to Entresto until July.